We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+13.04%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$587M
AUM Growth
-$222M
Cap. Flow
-$130M
Cap. Flow %
-22.12%
Top 10 Hldgs %
35.65%
Holding
170
New
43
Increased
23
Reduced
46
Closed
45

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$19.7M
2
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$16.8M
3
BIIB icon
Biogen
BIIB
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$8.46M
5
ORA icon
Ormat Technologies
ORA
+$7.92M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$24.8M
2
ABBV icon
AbbVie
ABBV
+$23.3M
3
AGN
Allergan Inc
AGN
+$23M
4
JNJ icon
Johnson & Johnson
JNJ
+$22.1M
5
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$14M

Sector Composition

Rank Sector Weight
1 Healthcare 68.95%
2 Miscellaneous 18.46%
3 Technology 5.1%
4 Industrials 3.71%
5 Energy 1.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVS icon
1
Novartis
NVS
$268B
$40.8M 6.96%
490,617
-43,859
-8% -$3.64M
AGN
2
DELISTED
Allergan plc
AGN
$27.6M 4.7%
107,100
-15,000
-12% -$3.75M
PFE icon
3
Pfizer
PFE
$158B
$27.2M 4.64%
921,210
-421,600
-31% -$12.1M
TEVA icon
4
Teva Pharmaceutical Industries Limited
TEVA
$45.7B
$22.8M 3.88%
396,269
-251,169
-39% -$14M
SLXP
5
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$18.2M 3.1%
158,500
+138,500
+693% +$16.8M
GILD icon
6
Gilead Sciences
GILD
$186B
$17.9M 3.05%
+190,000
New +$19.7M
SHPG
7
DELISTED
Shire pic
SHPG
$15.9M 2.71%
224,751
-34,334
-13% -$7.28M
BHC icon
8
Bausch Health
BHC
$2.13B
$14.1M 2.4%
98,550
– –
BIIB icon
9
Biogen
BIIB
$32.3B
$13.6M 2.31%
+40,000
New +$12.9M
ISRL
10
DELISTED
Isramco Inc
ISRL
$11.1M 1.9%
80,733
-100,483
-55% -$13.1M
UTHR icon
11
United Therapeutics
UTHR
$21.2B
$9.56M 1.63%
73,840
-15,000
-17% -$1.93M
MNK
12
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$9.01M 1.53%
90,940
-45,000
-33% -$4.14M
BMY icon
13
Bristol-Myers Squibb
BMY
$129B
$8.86M 1.51%
+150,000
New +$8.46M
ESLT icon
14
Elbit Systems
ESLT
$35.1B
$8.85M 1.51%
144,759
– –
VRNT
15
DELISTED
Verint Systems
VRNT
$8.52M 1.45%
286,810
-10,522
-4% -$307K
BMRN icon
16
BioMarin Pharmaceuticals
BMRN
$12.7B
$7.23M 1.23%
80,000
-41,970
-34% -$3.49M
BLCM
17
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$6.96M 1.19%
+33,151
New +$7.11M
IWM icon
18
iShares Russell 2000 ETF
IWM
$77.2B
$6.5M 1.11%
+54,300
New +$6.21M
KITE
19
DELISTED
Kite Pharma, Inc.
KITE
$6.4M 1.09%
110,970
+43,000
+63% +$1.81M
GCVRZ
20
DELISTED
Sanofi Contingent Value Rights
GCVRZ
$6.22M 1.06%
67,960
– –
AZN icon
21
AstraZeneca
AZN
$257B
$6.1M 1.04%
86,637
-33,363
-28% -$2.39M
LLY icon
22
Eli Lilly
LLY
$1.02T
$6.01M 1.02%
87,100
-10,000
-10% -$675K
PCYC
23
DELISTED
PHARMACYCLICS INC
PCYC
$5.97M 1.02%
48,840
+10,000
+26% +$1.28M
AAPL icon
24
Apple
AAPL
$4.9T
$5.83M 0.99%
211,212
+11,032
+6% +$300K
ASPX
25
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$5.78M 0.98%
110,074
-55,000
-33% -$1.62M
1
2 3 4 5

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q4 2014 Portfolio in Review

As of Q4 2014, Sphera Funds Management held 170 positions worth $587M, down 27% from $809M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Sphera Funds Management withdrew a net $130M in Q4 2014, closing 45 positions and reducing 46 holdings. Its most notable exit was Merck, an estimated $24.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 60% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Sphera Funds Management opened a new position in Gilead Sciences worth $17.9M.

  • Sphera Funds Management's largest Q4 2014 buy was Gilead Sciences: 190,000 shares worth $17.9M.
  • Sphera Funds Management added most to SALIX PHARMACEUTICALS LTD DEL in Q4 2014, an estimated $16.8M increase.
  • Sphera Funds Management's biggest Q4 2014 reduction was Teva Pharmaceutical Industries Limited, cutting an estimated $14M.
  • Sphera Funds Management fully exited Merck in Q4 2014, selling an estimated $24.8M.
  • Sphera Funds Management's ten largest holdings make up 36% of its $587M portfolio in Q4 2014.
  • Sphera Funds Management opened 43 new positions and closed 45 in Q4 2014.
  • Sphera Funds Management's portfolio value fell 27% quarter-over-quarter to $587M.

Based on Sphera Funds Management's 13F filing for Q4 2014, filed 12 Feb 2015.